

REMARKS

Claims 61-82, and 84-100 presently appear in this case. No claims have yet been acted upon on the merits. All of the claims have been subjected to election/restriction requirement. Prompt consideration on the merits and allowance of all of the elected claims are hereby respectfully urged.

The examiner has required restriction under 35 U.S.C. 121 and 372 among the following groups of claims:

Group I, including claims 61-82, drawn to a method for transfecting a cell with a nucleic acid molecule comprising contacting said cell with a sphingoid-polyalkylamine conjugate with said nucleic acid molecule;

Group II, including claims 84-87, drawn to a method for the treatment of a disease or disorder comprising the administration of a sphingoid-polyalkylamine conjugate associated with a nucleic acid molecule; and

Group III, including claims 88-100, drawn to a transfection composition comprising a sphingoid-polyalkylamine conjugate and a nucleic acid molecule.

The examiner states that there is no single general inventive concept in light of Scherman.

Applicant hereby elects the invention of Group I, including claims 61-82.

Appln. No. 10/560,932
Amd. dated June 1, 2009
Reply to Office Action of March 30, 2009

Prompt consideration on the merits and allowance of all
of the elected claims are earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By /rlb/
Roger L. Browdy
Registration No. 25,618

RLB:pp
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
G:\BN\C\cohn\Barenholz14\pto\2009-06-01Amendment.doc